Duck source recombinant infectious bronchitis virus and application thereof

By isolating and identifying duck-derived recombinant infectious bronchitis virus (DIBVSD2401), and successfully proliferating it in chicken and duck embryo fibroblasts to prepare an inactivated vaccine, the problem of difficulty in culturing chicken infectious bronchitis virus in vitro in existing technologies has been solved, achieving efficient vaccine production and excellent immune protection.

CN122326544APending Publication Date: 2026-07-03SHANDONG AGRICULTURAL UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202510003904.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-01-02
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Existing technologies make it difficult to culture chicken infectious bronchitis virus in vitro, which leads to difficulties in vaccine development and production. Furthermore, the lack of cross-protection between different serotypes poses challenges to the diagnosis and prevention of IB.

Method used

A duck-derived recombinant infectious bronchitis virus strain DIBVSD2401 was isolated and identified, and successfully propagated in chicken and duck embryo fibroblasts to prepare an inactivated vaccine for the prevention or treatment of avian infectious bronchitis. Adjuvants were used to enhance the immune effect.

Benefits of technology

The duck-derived recombinant infectious bronchitis virus DIBVSD2401 showed good in vitro culture performance, and the prepared inactivated vaccine had excellent immunogenicity and protective effect, which could effectively prevent viral infection in ducklings and laying ducks and reduce production costs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a duck-origin recombinant infectious bronchitis virus and application thereof, and belongs to the field of separation and application of virus strains. The virus is preserved in the China Center for Type Culture Collection on December 26, 2024, and the preservation number of the virus is CCTCC NO: V202503. The duck-origin recombinant infectious bronchitis virus has infection capability on CEF and DEF cells, is convenient for in-vitro culture, and is suitable for production of high-quality inactivated vaccines with high antigen titer. The duck-origin recombinant infectious bronchitis virus DIBVSD2401 disclosed by the invention has excellent immunogenicity, and an inactivated vaccine prepared from the duck-origin recombinant infectious bronchitis virus DIBVSD2401 disclosed by the invention is good in safety and excellent in protection effect.
Need to check novelty before this filing date? Find Prior Art